ombrabulin

Known as: (2S)-2-amino-3-hydroxy-n-(2-methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)phenyl)propanamide 
A synthetic water-soluble analogue of combretastatin A4, derived from the South African willow bush (Combretum caffrum), with potential vascular… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
02420122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background The combination use of the vascular disrupting agent ombrabulin with chemotherapeutic agents was previously shown to… (More)
Is this relevant?
2016
2016
OBJECTIVE In clinical studies in Western countries, the recommended dose of combination ombrabulin a vascular disrupting agent… (More)
Is this relevant?
2015
2015
BACKGROUND Ombrabulin (AVE8062) disrupts the vasculature of established tumours and has shown preclinical synergistic anti-tumour… (More)
Is this relevant?
2014
2014
Background:The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo. Recommended phase II doses were… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2014
2014
BACKGROUND DISRUPT evaluated whether adding the vascular-disrupting agent ombrabulin to a taxane-platinum doublet in the first… (More)
Is this relevant?
2014
2014
Purpose Preclinical evidence supports synergy between the vascular disrupting agent ombrabulin and various chemotherapy agents… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2014
2014
To determine ombrabulin’s maximum tolerated dose and dose recommended for Japanese patients with advanced solid tumors and to… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2013
2013
PURPOSE The vascular disrupting agent ombrabulin rapidly reduces tumor blood flow and causes necrosis in vivo. A phase I dose… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2012
2012
Targeting tumor vasculature is an emerging strategy in cancer treatment. Promising results have been shown in preclinical studies… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Review
2012
Review
2012
In the last decades, the active research in the field of tumor angiogenesis has led to the development of a class of agents… (More)
Is this relevant?